Description
Blend 300 is an oily injection solution containing three different anabolics at 100mg/ml each: Testosterone, Masteron (Drostanolone), and Trenbolone. The ester variants of individual compounds vary by manufacturer - typical are Test Propionate, Masteron Propionate, and Trenbolone Acetate for a synchronized short half-life profile.
Per study reports TMT combines the complementary action profiles of the three compounds: Test as base androgen with estrogen component, Masteron as dry DHT derivative with anti-estrogen action, Trenbolone as highly-potent 19-nor compound without aromatization but with progestagenic residual action.
The typical cutting research effects are the sum of individual compounds: dry muscle quality through Masteron, sharp androgenic action through Trenbolone, anabolic plateau through Test. Water retention stays low thanks to the two DHT/19-nor components balancing estrogen effects of the test portion.
In practice TMT is injected twice per week or more often, depending on used esters. With propionate variant typically every 1-2 days. The single injection with three compounds reduces volume and number of pricks.
Known effects are the sum of individual compounds: Tren-typical night sweats, sleep disturbances, aggression; Masteron-typical hardness; Test-typical water retention (mitigated by the others). Cabergoline accompaniment is important due to the Tren portion.
You can order Blend 300 as an oily injection solution in 10-pack at 300mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
TMT blends bundle the risk profiles of three anabolics into one injection - the effects described in the literature are the sum of the individual compounds and correspondingly broad.
Documented in studies and the application literature:
- Trenbolone portion: as a 19-nor compound with progestagenic residual action, elevated prolactin levels, night sweats, sleep disturbances and aggression are documented. Trenbolone does not aromatize.
- Test portion: the testosterone portion aromatizes to estradiol, with documented water retention and at higher doses gynecomastia risk, mitigated by the two DHT/19-nor components.
- Suppression of endogenous production: all three compounds throttle the body’s own testosterone production via the HPTA axis. Testicular atrophy and reduced fertility are documented.
- Cardiovascular: the literature describes unfavorable shifts in the lipid profile (HDL falls), elevated hematocrit and an associated thrombosis risk.
- Other: acne, accelerated hair loss with genetic predisposition, strain on injection sites from the frequent application.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men - NEJM 1996, Bhasin et al: classical dose-response study on testosterone effects on muscle mass and strength.
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - Am J Physiol Endocrinol Metab 2011, Yarrow et al: animal study on tissue-selective anabolic action of trenbolone.
- Transcriptional regulation of myotrophic actions by testosterone and trenbolone on androgen-responsive muscle - Steroids 2014, Ye et al: gene-expression comparison of testosterone and trenbolone on muscle transcriptome.
- A dose-response evaluation of androgens in the treatment of metastatic breast cancer - Cancer 1973, Talley et al: controlled study on dromostanolone (Masteron) in metastatic breast cancer.
- Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement - Endocrine Reviews 2014, Pope et al: Endocrine Society consensus on cardiovascular, endocrine and metabolic effects of AAS.
